The capacity of E1A gene-deleted and thus replicationdefective adenovirus type 5 (Ad5) to transduce foreign genes in chicken embryo fibroblasts (CEF) as well as in chickens was investigated. The lacZ and luciferase genes were successfully transduced in CEF by replicationdefective Ad5, demonstrating that these cells possess receptor(s) for binding and penetration of Ad5. A single intramuscular inoculation of Ad-gD, a replicationdefective Ad5 harbouring the gD gene of pseudorabies virus, in adult and 1-day-old chickens led to the production of very high titres of specific antibodies. These gD-specific antibodies persisted for at least 56 days. These results demonstrate that replication-defective Ad5, despite its mammalian origin and the deletion of the EIA gene, is a good candidate for developing non-spreading vaccines in poultry.
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Until recently, in contrast to mammalian species, fewer efforts have been made to develop recombinant virusvectored vaccines for avian species. Among poxvirusbased vectors, fowlpox and vaccinia viruses expressing the haemagglutin or the neuraminidase antigens have been shown to protect chickens against influenza (Boursnell et al., 1990; Chambers et al., 1988; Webster et al., 1991) . Fowlpox virus recombinants expressing proteins from Marek's disease virus have also been developed (Yanagida et al., 1992) . A pigeonpox virus expressing the fusion glycoprotein of Newcastle disease virus (NDV) was able to protect chickens against NDV challenge (Letellier et aL, 1991) . Herpesviruses (infectious laryngotracheitis virus and herpesvirus of turkeys) are also being developed as virus vectors (Morgan et al., 1992; Sondermeijer et al., 1993; Guo et al., 1994) . However, all these recombinant viruses are able to replicate in target birds and the risk of horizontal spreading of such recombinant viruses remains to be assessed.
Use of replication-defective viruses can be a way to combine biosafety and efficiency. Canarypox viruses (Taylor et al., 1992) and replication-defective adenoviruses have been shown to efficiently overcome protective immunity in mammalian species. Recombinant replication-defective adenoviruses are constructed by deleting the EIA or the E1A/E1B genes in such a way that the viral cycle is blocked in the early phase. (Oualikene et al., 1994) . These kinds of viruses are currently being studied as viral vectors for gene therapy and for vaccination purposes. Some properties of these viruses are very promising (for a review, see Ali et al., 1994): first, adenoviruses are able to introduce foreign genes into a wide spectrum of cells including muscle, epithelial, neuronal and macrophage cells; secondly, viral DNA is maintained mainly as an episome for several weeks or even months, the transduced gene being expressed during this time in such a way that a longlasting immune response can be expected. Moreover, despite its human origin, this virus is able to target foreign genes in a wide range of animal species, even those in which adenovirus type 5 (Ad5) cannot replicate. Dogs, cattle (Prevec et al., 1989) , mice (Eloit et al., 1990; Jacobs et al., 1994) , rabbits (Eloit et aI., 1990) , monkeys (Ballay et al., 1987; Natuk et al., 1993; Prevec et al., 1991 ; Ragot et al., 1993) , pigs (Adam et al., 1994) , cats (Gonin et al., 1995) and rats (W. Oualikene, unpublished) chicken embryo cells can be transduced successfully with Ad5, and that chickens inoculated by the intramuscular route exhibit a high antibody response against the transduced foreign protein.
The construction of Ad-gD, formerly referenced as Ad-gp50, has been described previously (Eloit et al., 1990) . Briefly, the gD gene (formerly known as gp50) of the pseudorabies virus (PRV) NIA3 strain under the control of the major late promoter (MLP) of adenovirus type 2 (Ad2) was inserted at the very left end of Ad5, into the E 1A gene. Other viruses were constructed in a similar way and will be described in detail elsewhere: Ad-gag, Ad-BgaI and Ad-luc express, respectively, the gag gene of the Villefranche strain of feline immunodeficiency virus, a fl-galactosidase gene with the simian virus 40 (SV40) nuclear localization signal and the firefly luciferase gene. All of these genes are transcribed from the MLP. Virus stocks were amplified in 293 cells, a cell line which provides phenotypic complementation of the E1 genes (Graham et al., 1977) , and were purified by banding twice in a CsC1 gradient to avoid carrying-over free proteins. Virus stocks were titrated in the same cell line and titres were expressed as TCIDs0.
In order to check the ability of Ad5 to transfer foreign genes into avian cells, chicken embryo fibroblasts (CEF) were prepared by digestion of 9-day-old chicken embryos with pronase and maintained in Eagle's medium modified according to the method of MacPherson & Stoker (1962) . They were infected with Ad-BgaI at an m.o.i, of 100, 1000 and 10000 TCIDs0 per cell and analysed 48 h later by chemical staining for fl-galactosidase activity. A characteristic staining of cells, mainly localized in the nuclei, was found in cells inoculated at an m.o.i, of 10 ~ TCIDso/cell (Fig. 1) . LacZ activity was not detectable either in cells inoculated at an m.o.i, of either 103 or 102 TCIDso/cell, or in cells infected with a non-relevant adenovirus (Ad-gD). No evidence of morphological alterations of the cells was seen even at the highest m.o.i. To provide further evidence that Ad5 can transduce foreign genes into CEF, separate cultures were infected with Ad-luc. Monkey Vero, murine 3T3 and human A549 cells were tested in parallel. Luciferase activity was assayed 48 h after infection (Fig. 2) . Luciferase activity was found in Ad-luc-infected CEF and increased with the m.o.i. Luciferase activity was demonstrated at a lower m.o.i. (100TCIDs0/cell) than fl-galactosidase activity, most probably due to the higher sensitivity of the luciferase assay. No significant activity was found in non-infected control cells (data not shown). The efficiency of gene transduction in CEF was dearly lower than that seen in A549 cells but roughly equivalent to that recorded in Vero and 3T3 cells, at least in the range 10-1000 TCIDs0 per cell.
From the experiments conducted in CEF, it is obvious that Ad5 is able to introduce foreign genes into avian cells, which means that the first steps of infection occur in these CEF cells. Ad2 (closely related to type 5) binds by the fibre protein to a cellular receptor which is as yet unknown, then penetrates into cells by endocytosis (Haywood, 1994; Louis et al., 1994) . This receptormediated endocytosis is dependent on interactions between the penton base and integrins ~vfl3 and ~vfl5 (Defer et al., 1990; Mathias et aI., 1994) . Virions are then released into the cytoplasm by disrupting the membrane of the endocytic vesicles by a mechanism which involves the penton base and requires a low pH (Seth, 1994) . Then, the modified virions migrate to the nucleoplasm. Our results indirectly show that avian cells possess the receptor(s) necessary for binding and penetration of the virions, and that the penton base of Ad5 is probably able to disrupt the membrane of the endocytic vesicles. These findings are consistent with those demonstrating that CELO virus (avian adenovirus type 1) is able to enter into mammalian cells, albeit with low efficiency (Cooten et al., 1993) . In our experiments, high m.o.i, values (at least 100 TCIDs0/cell ) were necessary to induce significant levels of the foreign gene product. This result is similar to that recorded in Vero and 3T3 cells. This can be related either to a low number of receptors on CEF or to a low efficiency of the MLP promoter in avian cells. There is a low density of Ad receptors on 3T3 fibroblasts , which reduces the efficiency but does not prevent the targeting of foreign genes in mice. In future constructions, the use of strong promoters from avian viruses, like the LTR from Rous sarcoma virus, will enable the potential weakness of the MLP promoter to be bypassed.
Based on these results, in vivo experiments were conducted to investigate whether Ad5 would induce an immune response against a foreign gene in chickens. In a first trial, the efficacy of the muscular route (wing muscles) was investigated. Six-week-old specificpathogen-free (SPF) chickens were distributed between three isolators. In the first isolator, 10 chickens were inoculated by the intramuscular route with 0'5 ml of sample containing 109 TCIDs0 of Ad-gD and five noninoculated chickens were left in contact as controls. In the second isolator, the same experiment was carried out, using Ad-gag. In the third isolator, 10 chickens were left as controls. Serum samples were taken at day 0 and at day 21. Antibodies raised against gD were titrated by a previously described ELISA using purified envelope proteins of PRV as the antigen (Eloit et al., 1990) , with biotinylated anti-chicken Ig (Amersham) and streptavidin horseradish peroxidase conjugate (Amersham). Titres were expressed as the last dilution which gave an absorbance greater than the average absorbance reading for the non-vaccinated chickens plus 0"150. Specific antibody responses were found 3 weeks after the first inoculation (Table 1 ). All the chickens demonstrated very high titres of antibodies, ranging from 10240 to 163040 (geometric mean 38000). In contrast, no specific PRV antibodies could be found either in chickens inoculated with Ad-gag or in noninoculated chickens in contact with Ad-gD-inoculated birds. The specificity of the antibody responses was also demonstrated by the ability of the sera from Ad-gDinoculated animals to neutralize PRV in a microneutralization test using a 1 h contact between serum and virus and without adding complement (Vannier et al., 1991) (data not shown). There was no elevation of antibody titres after boosting the chickens 3 weeks after the first inoculation. Neutralizing antibodies raised against Ad5 were tested by a microneutralization test in 293 cells, using 100 TCIDs0 of Ad5 and a 1 h incubation time. A clear boost effect was recorded (Table 1) . At day 21 (the time of the boost inoculation), the geometric mean of Ad5 neutralizing antibodies was 12. Three weeks after the boost (day 42), the geometric mean was 166. Antibodies raised against avian adenovirus type 1 (CELO virus) were tested by agar gel immunodiffusion as described by Beard (1970) in all samples and gave negative results in all cases.
In the second trial, inoculation by the ocular or nasal route was investigated. Four groups of five 1-day-old SPF chickens were maintained in the same isolator. Three groups were vaccinated with 0'03 ml (ocular route and nasal route) or 0"1 ml (intramuscular route) of sample containing 109TCID~0 of Ad-gD and kept isolated from other groups for 4 h before they were mixed in the isolator. One group of untreated chickens was left in contact. Another group of five untreated chickens was maintained in another isolator as a control. Results are given in Table 1 . No antibody response could be found in chickens inoculated by the local routes (i.e. nasal and ocular). In contrast, out of five chickens inoculated i.m., four developed high antibody titres which persisted for at least 56 days.
These results demonstrate that chickens inoculated by the intramuscular route develop very high levels of antibodies after a single injection in adult chickens. Antibodies in 1-day-old vaccinated chickens persisted at least for 56 days. No increase in antibody titres could be * In trial 1, 6-week-old SPF chickens were inoculated intramuscularly (i.m.) at day 0 with Ad-gD or Ad-gag as control. Groups of non-inoculated chickens were left in contact in the same isolators. Chickens inoculated with Ad-gD were boosted at day 21. In trial 2, chickens were injected with Ad-gD by different routes of administration at day 0 and were not boosted. When all chickens gave the same result, only this single value is shown. Where individual antibody titres are given, values are arranged in the same relative sequence so that consecutive results for each chicken can be identified.
t Antibody titre against gD. Neutralizing antibody titre against Ad5. ND, Not done. found after boosting adult chickens which had been vaccinated 3 weeks before. This could be due to either the very high titres against gD obtained after the first injection which made it impossible to observe a boost effect, or a strong immune response against the vector that developed after the first inoculation. All the chickens possessed neutralizing antibodies against Ad5 at the time of the boost (Table 1) , and it is currently well known that such an immune response considerably decreases the efficiency of transduction of the foreign gene in subsequent injections (Kasseisler et al., 1994) . On the other hand, no antibody responses could be demonstrated after local administration of the recombinant virus. Lack of antibody response was also demonstrated in chickens vaccinated once by the ocular route with a recombinant fowlpox virus expressing the F protein of NDV (Taylor et al., 1992) . This does not mean that the chickens did not exhibit a mucosal immune response, as this has yet to be investigated.
Our results show that replication-deficient Ad5, despite its mammalian origin, is able to introduce foreign genes into avian cells and can be used as a virus vector in chickens for the development of a new generation of vaccines. It can be anticipated that, in addition to the antibody response, intracellular synthesis of immunogenic proteins should be able to induce the development of a cytotoxic T cell response, as demonstrated for adenovirus-based vaccines in mammals (Jacobs, 1993) . The safety requirements for these adenovirus-vectored vaccines should be met by (i) the deletion of the EIA gene (Oualikene et al., 1994) , (ii) the lack of complementation of the E1A gene by its counterpart in avian adenovirus in the case of superinfection by a wild-type (wt) virus (Li et al., 1984) , and (iii) the inability of Ad5 wt to develop a productive cycle in avian cells. The next step in our work will be to use new constructions harbouring an immunogenic protein of an avian pathogen in order to investigate the mucosal immunity induced by local routes of vaccination.
